Large caps are the best in the biotech sector

Within the 'Biotechnology', we see a low diversification of the 12-months returns. Since November last year the sector is around 11 percent higher. Among the winners we find Avita Medical, Shield Therapeutics and Veloxis Pharmaceuticals A/S. Relatively big losses were for OpGen, Tocagen and Inflarx NV.

Core figures 'Biotechnology'

The large caps in this sector are the winners. Among the less performing are mostly the smallcaps.

Lowest PE-ratios 'Biotechnology'

Regarding the price/earnings-ratios we see a diversified palette. The large caps are with the price/earnings-ratio of 25 the most expensive. The smallcaps are the cheapest and trade at -6 times the earnings per share. Diaceutics, Abcam and Genus are the stocks with the highest ratios. Stocks with the lowest ratios are Endo International, Mylan NV and Arena Pharmaceuticals.

Highest dividend yields 'Biotechnology'

The sector's average dividend yield is with 0.6 percent relatively limited. Stocks now high dividend yields now are Abbvie, Bayer AG and Gilead Sciences.

This is a free publication from Valuespectrum Pro. Valuespectrum Pro is a professional platform with analyses from all US and European companies. Click here to sign up for free.